# Praluent

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/praluent
Canonical HTML page: https://getyourbrief.com/entity/praluent

## Timeline

- **2026-07-16**: FDA Approves Lipfendra — The FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, for adults with hypercholesterolemia including inherited forms, based on Phase 3 CORALreef trials showing 56-59% LDL-C reduction.

## Recent coverage (2 stories, network-wide)

### New pill cuts LDL 59%: How Lipfendra could change cholesterol care for millions
2026-07-16 22:00:46 · Sector: health · Sentiment: Strongly positive · Impact: 9/10 · Sources: 132

The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol.
Full story: https://gethealthbrief.com/story/lipfendra-oral-pcsk9-lowers-ldl-59-percent-patient-access

### Merck’s oral PCSK9 inhibitor hits 59% LDL cut, leapfrogging injectable rivals
2026-07-16 22:00:10 · Sector: bio · Sentiment: Strongly positive · Impact: 9/10 · Sources: 132

Merck won FDA approval for Lipfendra, a small-molecule oral PCSK9 inhibitor that achieved 56-59% LDL-C reductions in Phase 3. This breakthrough in oral delivery challenges the dominance of injectable biologics from Amgen and Sanofi/Regeneron.
Full story: https://getbiobrief.com/story/merck-lipfendra-fda-approval-oral-pcsk9-59-percent

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.